Skip to main content
Hit enter to search or ESC to close
Close Search
Hepion PharmaceuticalsHepion Pharmaceuticals
Menu
  • About
    • Company Overview
    • Executive Team
    • Board of Directors
    • Partnering
  • Hepatocellular Carcinoma
  • Portfolio
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
  • linkedin
Hepion Pharmaceuticals
Media Placements

Can Hepion Pharmaceuticals Develop the First Treatment Approved For NASH? With Robert Foster, Pharm D, PhD [Biotech IQ]

By HepionMay 4, 2022No Comments
https://hepionpharma.com/wp-content/uploads/2022/05/47-can-hepion-pharmaceuticals-develop-the-first-treatment-approved-for-nash-with-robert-foster-pharm-d-phd.mp3
About
Leadership
Hepatocellular Carcinoma
Portfolio
Newsroom
Contact
Subscribe for Updates

© 2026 Hepion Pharmaceuticals | Disclaimer & Terms of Use

Share
Share Share Share Pin
Close Menu
  • About
    • Company Overview
    • Executive Team
    • Board of Directors
    • Partnering
  • Hepatocellular Carcinoma
  • Portfolio
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
  • linkedin